FDA expands Dupixent indication, EU application to follow
Sanofi and Regeneron’s eczema treatment Dupixent is now approved for use in babies as young as six months old in the US.
by mikkel aabenhus hemmingsen, translated by catherine brett
Eczema treatment Dupixent can now be used by an even wider group of patients in the US, as the FDA has approved an application to extend the use of the drug.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Leo Pharma looking for pediatric patients for eczema trial
For subscribers
Analyst predicts slow start for Leo Pharma's Adtralza in UK
For subscribers
Dupixent drives sales advancement in Sanofi's first quarter
For subscribers
